|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.670 JOD | -0.60% |
|
-0.60% | +4.38% |
| 04-27 | Philadelphia Pharmaceuticals Q1 profit 255,632 dinars | RE |
| 04-26 | Philadelphia Pharmaceuticals Company Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Market Cap | 12.52M 17.67M 15.25M 14.02M 13.19M 24.79M 1.67B 25M 166M 64.67M 819M 66.33M 64.91M 2.83B | P/E 2024 |
13.7x | P/E 2025 | 11.9x |
|---|---|---|---|---|---|
| Enterprise Value | 12.46M 17.58M 15.16M 13.94M 13.12M 24.66M 1.66B 24.86M 165M 64.32M 814M 65.97M 64.56M 2.82B | EV / Sales 2024 |
1.32x | EV / Sales 2025 | 1.3x |
| Free-Float |
7.27% | Yield 2024 |
4.67% | Yield 2025 | - |
| 1 day | -0.60% | ||
| 1 week | -0.60% | ||
| Current month | -2.91% | ||
| 1 month | +1.21% | ||
| 3 months | +5.03% | ||
| 6 months | +7.74% | ||
| Current year | +4.38% |
| 1 week | 1.67 | 1.67 | |
| 1 month | 1.66 | 1.74 | |
| Current year | 1.5 | 1.74 | |
| 1 year | 1.45 | 1.74 | |
| 3 years | 1.34 | 1.74 | |
| 5 years | 1.28 | 1.74 | |
| 10 years | 1.28 | 3.42 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ashraf Hussein
CEO | Chief Executive Officer | 44 | 2012-12-31 |
Rima Shanoudeh
CTO | Chief Tech/Sci/R&D Officer | - | - |
Belal Salameh
DFI | Director of Finance/CFO | 50 | 2001-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Munther Hussein
CHM | Chairman | 58 | - |
| Director/Board Member | 61 | 2016-08-31 | |
| Director/Board Member | 64 | 2012-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.60% | -0.60% | +14.38% | +28.46% | 17.78M | ||
| +1.09% | +2.33% | +8.02% | +83.51% | 45.7B | ||
| +2.03% | +2.87% | +46.54% | +90.11% | 34B | ||
| -1.63% | -1.87% | -11.54% | +34.27% | 11.73B | ||
| -1.60% | -4.00% | +8.93% | +92.61% | 11.48B | ||
| +1.99% | +3.12% | +39.68% | +130.57% | 9.28B | ||
| -0.92% | -0.17% | +16.72% | +41.32% | 7.21B | ||
| -0.42% | +1.63% | +44.06% | -18.50% | 6.62B | ||
| -0.93% | -3.30% | +26.92% | +232.57% | 6.44B | ||
| -0.63% | -4.16% | -44.00% | -7.82% | 5.01B | ||
| Average | -0.16% | +0.08% | +14.97% | +70.71% | 13.75B | |
| Weighted average by Cap. | +0.59% | +0.50% | +19.27% | +81.40% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 8.76M 12.36M 10.67M 9.81M 9.23M 17.34M 1.17B 17.49M 116M 45.24M 573M 46.4M 45.41M 1.98B | 9.17M 12.94M 11.16M 10.26M 9.66M 18.15M 1.22B 18.3M 122M 47.34M 599M 48.55M 47.52M 2.07B |
| Net income | 822K 1.16M 1M 919K 865K 1.63M 109M 1.64M 10.89M 4.24M 53.69M 4.35M 4.26M 186M | 1.01M 1.42M 1.22M 1.12M 1.06M 1.99M 134M 2.01M 13.33M 5.19M 65.69M 5.32M 5.21M 227M |
| Net Debt | 334K 471K 406K 373K 351K 660K 44.42M 666K 4.42M 1.72M 21.8M 1.77M 1.73M 75.42M | -67.69K -95.5K -82.39K -75.75K -71.29K -134K -9.01M -135K -898K -349K -4.42M -358K -351K -15.3M |
Employees
129
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-16 | 1.670 JOD | -0.60% | 85 |
- Stock Market
- Stocks
- PHIL Stock
Select your edition
All financial news and data tailored to specific country editions
















